Edenbridge Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for EDENBRIDGE PHARMS

EDENBRIDGE PHARMS has twelve approved drugs.

There are ten US patents protecting EDENBRIDGE PHARMS drugs.

Summary for Edenbridge Pharms

US Patents:	10
Tradenames:	12
Ingredients:	12
NDAs:	12

Drugs and US Patents for Edenbridge Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-001	Jul 3, 2013		RX	Yes	No	8,940,330		Y
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-003	Dec 11, 2014		RX	Yes	No	9,259,421		Y
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-003	Dec 11, 2014		RX	Yes	No	9,439,900		Y
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-003	Dec 11, 2014		RX	Yes	No	8,470,361		Y

Expired US Patents for Edenbridge Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-001	Jul 3, 2013	8,454,996
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-002	Jul 3, 2013	8,454,996
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-006	Oct 4, 2016	8,454,996
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-004	Dec 11, 2014	8,454,996

Paragraph IV (Patent) Challenges for EDENBRIDGE PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Sublingual Tablets	2.9 mg/7.1 mg		2015-12-21
	Sublingual Tablets	8.6 mg/2.1 mg and 11.4 mg/2.9 mg		2015-07-24
	Sublingual tablets	0.7 mg/0.18 mg		2017-05-03
	Sublingual Tablets	1.4 mg/0.36 mg and 5.7 mg/1.4 mg		2013-10-22

International Patents for Edenbridge Pharms Drugs

Country	Patent Number	Estimated Expiration
Israel	230528
Chile	2014000575
Slovenia	2915525
San Marino	T201500126

Supplementary Protection Certificates for Edenbridge Pharms Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435024	202140009	Slovenia		PRODUCT NAME: COMBINATION OF FORMOTEROL (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF), GLYCOPYRROLATE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF) AND BUDESONIDE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF); NATIONAL AUTHORISATION NUMBER: EU/1/20/1498; DATE OF NATIONAL AUTHORISATION: 20201209; AUTHORITY FOR NATIONAL AUTHORISATION: EU
3209302	C202330028	Spain		PRODUCT NAME: COMBINACION DE FOSLEVODOPA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA Y FOSCARBIDOPA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISM.; NATIONAL AUTHORISATION NUMBER: 88677-SE/H/0415/003/DC; DATE OF AUTHORISATION: 20230220; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 141371; DATE OF FIRST AUTHORISATION IN EEA: 20220825
3209302	301224	Netherlands		PRODUCT NAME: COMBINATIE VAN FOSLEVODOPA EN FOSCARBIDOPA, ELK DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NATIONAL REGISTRATION NO/DATE: RVG128752 20221107; FIRST REGISTRATION: AT 141371 20220826
1620113	C 2015 036	Romania		PRODUCT NAME: IVERMECTINA; NATIONAL AUTHORISATION NUMBER: RO7674/2015/01, RO7674/2015/02, RO7674/2015/03, RO7674/2015/04, RO7674/2015/05; DATE OF NATIONAL AUTHORISATION: 20150526; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): MALTA MA117/01101; DATE OF FIRST AUTHORISATION IN EEA: 20150402

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Edenbridge Pharms